

## CUSTOMER UPDATE

Friday, 12 July 2019

### Progress update on Mo-99 production

ANSTO has maintained production of Mo-99 for all Australian customers over the past two weeks despite the temporary shutdown of the ANSTO Nuclear Medicine (ANM) facility.

Since the nuclear safety regulator, ARPANSA, granted ANSTO a limited licence to recommence the manufacture of Mo-99 in the ANM facility, two production runs have been successfully completed. These runs have progressed as planned and the Mo-99 has been utilised in Gentech<sup>®</sup> generators. Due to the two week shutdown of ANM coinciding with a scheduled shutdown of the OPAL reactor for maintenance, the yields of Mo-99 that have been recovered have been lower than usual.

As a result of the lower Mo-99 yields, there is a chance that your generator delivery may be affected:

- On Sunday, 14 July 2019, a limited number of sites may have their generator delivery delayed to Thursday 18 July. We do not anticipate this will affect more than five (5) sites nationally, and these sites will be contacted on Sunday to be advised
- A number of sites are currently receiving their Gentech<sup>®</sup> generator delivery earlier than required due to ANSTO's changed production days. The majority of these sites will have their generator deliveries re-scheduled to Monday 22 July 2019. This is to ensure adequate Mo-99 availability for sites that would normally receive a generator on a Wednesday, Thursday or Friday.

Individual sites affected by any of the above changes will be directly contacted by ANSTO in the coming days.

It is anticipated that the Mo-99 yields from ANM will be increasing over the coming few days, which will allow Gentech<sup>®</sup> generator manufacture to return to normal.

ANSTO would like to take this opportunity to thank the Australian nuclear medicine community for its support over this recent period.

Should there be any change to the status of the supply of Mo-99 from ANM within the Australian market, ANSTO will advise key stakeholders and the nuclear medicine community as a matter of priority. In the meantime, if you have any questions or are seeking more information, please contact us directly on 1800 251 572.

*To keep up to date with news on ANSTO's health products and services, you can also join our new community group on LinkedIn:*

***ANSTO's Australian Nuclear Medicine network***